PharmaMar and Key Oncologics have signed an exclusive agreement to commercialize Yondelis® in the Republic of South Africa, Namibia and Botswana

Madrid, May 19th, 2020. – PharmaMar (MSE:PHM) and Key Oncologics (Pty) Ltd announced today an exclusive licensing agreement for the importation, use, marketing, sale and distribution of the marine-derived anticancer drug Yondelis® (trabectedin) in South Africa, Namibia and Botswana.

The parties agreed not to disclose deal financials. PharmaMar will retain exclusive production rights for the product, which will be sold to Key Oncologics for its clinical and commercial use.

This new agreement follows PharmaMar's announcement on August 26th, 2019 regarding the agreement with Janssen Products LP (Janssen), by which PharmaMar recovered from Janssen the commercialization rights of the product in all the countries previously licensed, with the exception of the U.S., including rights in more than 40 countries where trabectedin had already been approved.

Yondelis® (trabectedin) received regulatory approval for the treatment of Soft Tissue Sarcoma and also for recurrent Ovarian Cancer in the Republic of South Africa, where Key Oncologics will take the lead to make the drug available to patients.

Through Key Oncologics, PharmaMar expects to see this compound accessing the markets of Namibia and Botswana, where trabectedin has not been available to date.

"We are proud to have partnered Yondelis® with Key Oncologics for these African territories. We believe that Key Oncologics' infrastructure and internal capabilities play a key role in helping us maximize access to this unique drug for as many sarcoma and ovarian cancer patients as possible in these territories, and we look forward to a long and mutually beneficial partnership with Key Oncologics" said Heiner Pieper, Vice-President of Business Development & Licensing at PharmaMar.
Announcing the new licensing collaboration, Magriet de Wet, CEO of Key Oncologics, said “We are very pleased to partner with PharmaMar, a company that shares our values, and are excited about the opportunity that Yondelis® represents for Key Oncologics and for sarcoma and ovarian cancer patients in South Africa, Namibia and Botswana. Yondelis® provides an exciting opportunity to grow our portfolio and further strengthen our leadership position in the Haematology/Oncology market in the territories. We look forward to many more years of a mutually beneficial association.”

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Key Oncologics
Key Oncologics (Pty) Ltd is a South African pharmaceutical company that primarily focuses on the treatment of cancer and allied diseases. The company was founded in 1998 representing international companies that do not have an independent presence in South Africa. Over the years our product profile has grown from a single product to a comprehensive portfolio. We have also diversified into biologics and are in the process of building a generic portfolio. In moving forward Key Oncologics will continue to seek options for patients to live longer and live better.

Key Oncologics (Pty) Ltd has experience in registering, marketing, selling and distributing cancer products in the South African market. We also have a clinical trial division with the necessary infrastructure to conduct Oncology Clinical Trials according to GCP.

About Yondelis®
Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from *Ecteinascidia turbinata*, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

**Media Contact:**
Alfonso Ortín – Communications Director  
aortin@pharmamar.com  
Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager  
mmartinez-cava@pharmamar.com  
Mobile: +34 606597464
Phone: +34 918466000

**Capital Markets & Investor Relations:**
José Luis Moreno– Capital Markets & Investor Relations Director  
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)